By Jorge G. Ruiz, MD
For decades, an Alzheimer’s disease diagnosis often came after memory loss had significantly altered a person’s daily life. By then, treatment options were limited, and families often faced difficult decisions with few effective resources.
Today, Alzheimer’s care is entering a new era. Advances in diagnostic testing, disease-modifying therapies and comprehensive memory care are transforming how we diagnose and treat the disease, helping patients maintain their independence longer while supporting families throughout every stage of care.
We can now diagnose Alzheimer’s disease earlier than ever before. Blood biomarker tests, spinal fluid analysis and amyloid PET imaging detect abnormal proteins such as amyloid and tau, which begin accumulating in the brain years before significant memory loss develops.
Biomarker testing is especially valuable for people with mild cognitive impairment or early memory changes because it helps physicians distinguish Alzheimer’s disease from other conditions with similar symptoms, including Lewy body disease, vascular cognitive impairment, frontotemporal dementia and even treatable medical conditions. Most importantly, it helps identify patients who may benefit from today’s disease-modifying therapies while giving families more time to plan, adopt healthy lifestyle changes and prepare for the future.
Recognizing when memory changes warrant evaluation is equally important. While occasional forgetfulness can be a normal part of aging, persistent memory changes that interfere with daily life should never be dismissed as “just getting older.”
Warning signs include repeatedly asking the same questions, getting lost in familiar places, difficulty managing medications or finances, trouble following conversations, or noticeable changes in judgment, behavior or personality. Family members are often the first to notice these changes. Memory problems, however, are not always caused by Alzheimer’s disease. Sleep apnea, depression, medication side effects, thyroid disorders and vitamin deficiencies can all affect memory and, in many cases, are treatable. Early evaluation helps ensure patients receive the right diagnosis and the most appropriate care.
Another major advancement is the availability of anti-amyloid infusion therapies for carefully selected patients with early Alzheimer’s disease. These medications remove amyloid, an abnormal protein that accumulates early in the disease process and appears to trigger a cascade of events that ultimately leads to tau buildup, nerve cell injury and cognitive decline. While these therapies are not a cure, they have been shown to slow disease progression, helping many patients maintain their independence and quality of life longer as researchers continue developing additional therapies.
At Memorial Healthcare System, our Memory Disorders Program is designed to care for patients from the earliest signs of cognitive change through advanced dementia. Comprehensive evaluations include neurological examinations, cognitive testing, brain MRI, blood biomarker testing, computerized cognitive assessments and amyloid PET imaging when appropriate. For eligible patients, we provide anti-amyloid infusion therapy with close MRI monitoring for safety while working closely with patients and families throughout every stage of care. Our goal is not only to diagnose Alzheimer’s disease but also to help patients maintain their independence and quality of life for as long as possible.
Alzheimer’s disease affects entire families, not just the patient. Caregivers are essential partners throughout the journey, and they need education, guidance and support. Memorial connects families with caregiver education, support groups, social services and community resources throughout Broward and Miami-Dade counties, including home care, respite services and long-term planning assistance.
Although Alzheimer’s disease remains one of medicine’s greatest challenges, the pace of research has never been more encouraging. Today, we have the first generation of disease-modifying therapies and a robust pipeline of promising new medications. Researchers are developing treatments that target not only amyloid, but also tau protein, brain inflammation, oxidative stress, insulin resistance, metabolism, synaptic dysfunction and other biological pathways. We are also learning that Alzheimer’s is driven by multiple interacting mechanisms rather than a single process. Much like cancer or cardiovascular disease, Alzheimer’s will likely be treated with personalized combinations of therapies tailored to each patient’s biomarkers and stage of disease.
The most important message for families is simple: don’t ignore memory loss. Early evaluation can identify treatable causes of cognitive impairment, determine whether Alzheimer’s disease is present and connect patients with therapies and comprehensive support services that can help them maintain independence and quality of life. The future gives me tremendous hope because today’s treatments are only the beginning.
Dr. Jorge G. Ruiz is Medical Director, Geriatric Medicine, Memorial Healthcare System.
